DUBLIN, July 26, 2017 /PRNewswire/ --
The "Oncology Drug Discovery Services Market, 2017-2030" report has been added to Research and Markets' offering.
The Oncology Drug Discovery Services Market, 2017-2030 report features an extensive study of the current market landscape and the future potential of CROs providing drug discovery services in oncology.
Cancer, one of the leading causes of death worldwide, is an extremely complex disease and medical science is still struggling to figure out the various factors associated with the disease's origin, propagation, spread (metastasis) and relapse. In fact, in 2017, a total of 1.7 million new cancer cases are estimated to be diagnosed in the US alone; during the same time period, close to 0.6 million patients are estimated to die due to cancer.
With the increasing complexity of drug discovery and development process, the overall spending on R&D in the pharmaceutical / biotechnology sector has increased over the past few years. According to one particular source, this spending has increased from USD 108 billion in 2006 to USD 145 billion in 2016.
Heavy investments are being made towards the discovery of novel approaches for the treatment of various types of cancers. The industry is currently under tremendous pressure not only to meet the expectations of a growing patient population but also to identify ways to address the risks associated with novel drug discovery programs. Over the years, CROs offering drug discovery services have contributed significantly and have now grown to become an integral and indispensable part of the pharmaceutical and biotechnology industry.
This study presents an in-depth analysis of a diverse set of companies that offer services across the different steps, such as target identification, target validation, hit generation, hit-to-lead and lead optimization, of the drug discovery process.
In addition, the study features a detailed analysis of the existing market size and the future growth potential of the oncology drug discovery services market for the period 2017-2030. We have provided insights on the likely regional evolution of the market, across North America, Europe, China and the rest of the world.
Additionally, we have provided informed estimates of the likely market evolution on the basis of type of product (small molecule, biologics) and key steps of drug discovery (target identification, target validation, hit generation, hit-to-lead and lead optimization). In order to account for the uncertainties associated with some of the key parameters, and to add robustness to our model, we have presented three different forecast scenarios, depicting the conservative, base and optimistic tracks of the market's evolution.
Key Topics Covered:
1. Preface
2. Executive Summary
3. Introduction
3.1. Chapter Overview
3.2. Drug Discovery and Development Timeline
3.3. Drug Discovery Process: History and Evolution
3.4. Current Drug Discovery Process
3.5. Drug Discovery Process: Steps Involved
3.5.1 Target Identification: Introduction and Approaches
3.5.1.1. Chemical Proteomic Based Approaches
3.5.1.2. Expression Cloning Techniques
3.5.1.3. In Silico Approach
3.5.2. Target Validation: Introduction and Approaches
3.5.2.1. Pre-genomic Methods
3.5.2.2. Post-genomic Methods
3.5.3. Hit Discovery: Introduction and Approaches
3.5.4. Hit-to-Lead: Introduction and Approaches
3.5.5. Lead Optimization: Introduction and Models
3.6. Challenges Associated With In-House Drug Discovery
3.7. Shift in Trend towards Outsourcing of Drug Discovery Services
3.8. Oncology at the Forefront of Drug Discovery Research
4. Market Overview
4.1. Chapter Overview
4.2. Oncology Drug Discovery CROs: Overall Landscape
5. CROs: End-to-End Service Providers
5.1. Chapter Overview
5.2. Charles River Laboratories
5.3. Evotec
5.4. GE Healthcare Life Sciences
5.5. GenScript
5.6. HD Biosciences (A Subsidiary of WuXi AppTec)
5.7. Vichem Chemie
6. CROs: Target Based Service Providers
6.1. Chapter Overview
6.2. Horizon Discovery
6.3. Mir Lifescience (Division of MIR Group)
7. CROs: Hit / Lead Based Service Providers
7.1. Chapter Overview
7.2. DIVERCHIM
7.3. GVK Biosciences (A Business Division of GVK)
7.4. NuChem Therapeutics
7.5. Prestwick Chemical (A Subsidiary of Bionomics)
7.6. Syncom
8. CROs: Lead Optimization Service Providers
8.1. Chapter Overview
8.2. Envigo
8.3. Onyx Scientific (A Subsidiary of Ipca Laboratories)
9. Market Sizing and Forecast
9.1. Chapter Overview
9.2. Forecast Methodology
9.3. Oncology Drug Discovery Services Market, 2017-2030 (USD Billion)
9.4. Oncology Drug Discovery Services Market, 2017-2030: Distribution by Region (USD Billion)
9.5. Oncology Drug Discovery Services Market, 2017-2030: Distribution by Nature of Molecule (USD Billion)
9.6. Oncology Drug Discovery Services Market, 2017-2030: Distribution by Type of Service (USD Billion)
10. Benchmark Analysis
10.1. Chapter Overview
10.2. Benchmark Analysis: Methodology
10.3. Benchmark Analysis: Peer Groups
11. Recent Collaborations
11.1. Chapter Overview
11.2. Partnership Models
11.3. Oncology Drug Discovery Service Providers: Recent Collaborations
11.3.1. Oncology Drug Discovery Partnerships: Cumulative Trend, 2014 - H1 2017
11.3.2. Oncology Drug Discovery Partnerships: Distribution by Type of Partnership
11.3.3. Oncology Drug Discovery Partnerships: Most Active Players
11.3.4. Oncology Drug Discovery Partnerships: Analysis by Experience, Number of Services and Activity
12. Future Growth Opportunities
12.1. Chapter Overview
12.2. Oncology Drug Discovery is on the Cutting Edge of Personalized Medicine
12.3. Growing Popularity of Biologics Demands Specialized Research Expertise
12.4. Orphan Cancer Indications Offer New Opportunities for CROs
12.5. Start-ups in Oncology Will Continue to Seek Increased Support of CROs
12.6. Technological Advancements to Cater to Complexities Associated with the Drug Discovery Process
12.6.1. Deep Learning Technology
12.6.2. Organoids and 3D Cell Culture Systems
12.6.3. Acoustic Droplet Ejection (ADE) Technology
12.6.4. CRISPR-Cas9 Gene Editing Technology
12.6.5. Cloud Based Technology Platforms
13. Survey Analysis
13.1. Chapter Overview
13.2. Seniority Level of Respondents
13.3. Type of Drug Discovery Service
13.4. Nature of Molecule
13.5. Depth of Service Portfolio
13.6. Likely Market Size
13.7. Likely Growth Rate
14. Conclusion
14.1. Outsourcing has Emerged as a Convenient Option for Drug Discovery and Early Stage Development
14.2. Currently, Europe Stands out as the Major Hub for CROs, followed by North America and Asia Pacific
14.3. Lead Generation and Lead Optimization are the Most Frequently Outsourced Operations
14.4. Flexible Partnership Models have Fostered Collaborations between Drug Developers and CROs
14.5. Innovative Technologies and Untapped Opportunity Areas are Anticipated to Drive Long-Term Growth
14.6. Driven by the growing demand for contract services, the market is expected to witness continuous growth in the foreseen future
15. Interview Transcripts
16. Appendix 1: Tabulated Data
17. Appendix 2: List of Companies and Organizations
- AbbVie
- Abzena
- Academic Medical Center Helsinki
- Actelion Pharmaceuticals
- ActivX Biosciences
- Addex Therapeutics
- Advinus Therapeutics
- Agilux Laboratories
- Agios Pharmaceuticals
- Albany Molecular Research
- AlphaGene
- AmorChem
- AnCoreX Therapeutics
- Anthem Biosciences
- APEIRON Biologics
- Aptuit
- Aquila BioMedical
- Aragen Bioscience
- Aris Pharmaceuticals
- ArQule
- Asahi Kasei Pharma
- Asclepia MedChem Solutions
- AsisChem
- Astex Therapeutics
- AstraZeneca
- Attana
- Aurelia Bioscience
- Aurigene
- Aurora Fine Chemicals
- Avvinity
- Axon Biochemicals
- Axon Medchem
- Axxam
- Babraham Institute
- Bayer Group
- Beactica
- BellBrook Labs
- Beryllium Discovery
- Bienta
- Biobide
- Biocon
- BioDiscovery Group
- BioDuro
- BioFocus DPI
- Biomedicum Genomics
- BioMotiv
- Bionaturis Group
- Bionomics
- BioNTech
- BioStructures
- Birkbeck College
- Blue Stream Laboratories
- British Columbia Cancer Agency
- C4X Discovery
- Cadiz University
- California Institute for Biomedical Research
- Caliper Life Sciences
- CanAm Bioresearch
- Cancer Research Technology
- Cancer Research UK
- Carrick Therapeutics
- Cayman Chemical
- Celgene
- Celsis Group
- Centauri Therapeutics
- Centro Nacional de Investigaciones Oncológicas
- Charles River Laboratories
- Charnwood Molecular
- ChemBridge
- ChemDiv
- ChemoGenics BioPharma
- Chemveda Life Sciences
- Child Health and Development Institute of Connection
- Clininvent
- CombinatoRx
- Confluence Discovery Technologies
- Covance
- CreaGen Biosciences
- CRELUX
- CrownBio
- Curadev Pharma
- Curis
- Cyprotex
- Dabur Group
- Dabur Research Foundation
- Daiichi Sankyo
- Dalton Pharma Services
- Dana-Farber Cancer Institute
- DavosPharma
- Debiopharm Group
- DIVERCHIM
- Domainex
- Dong-A ST
- Dr. Reddy's Laboratories
- EDELRIS
- Enamine
- Envigo
- Enzymlogic
- Epichem
- Epistem
- Eurofins Scientific
- Evotec
- Exiris
- Exquiron Biotech
- Exscientia
- Fannin Innovation Studio
- Felicitex Therapeutics
- FORMA Therapeutics
- Free University of Amsterdam
- Fusion Antibodies
- Galapagos
- GalChimia
- Galectin Therapeutics
- GE Healthcare Life Sciences
- Genentech
- Genomics Medicine Ireland
- GenScript
- GL Chemtec International
- GlaxoSmithKline
- Griffith University
- GVK Biosciences
- H3 Biomedicine
- Harlan Laboratories
- HD Biosciences
- Helmholtz Association
- HitGen
- Horizon Discovery
- HQL Pharmaceuticals
- Huntingdon Life Sciences
- Icagen
- iGEM
- Infinity Pharmaceuticals
- INOVOTION
- Inserm
- Insilico Medicine
- Institut du cancer de Montréal
- Institute for Research in Immunology and Cancer Commercialization of Research
- Institute of Cancer Research, London
- INTEGREX Research
- IntelliSyn
- IOTA Pharmaceuticals
- Ipca Laboratories
- Jagiellonian University
- Janssen Biotech
- Janssen Pharmaceuticals
- Jinan Nornoon Biological Engineering
- Johnson & Johnson
- Joseph Fourier University
- JPT Peptide Technologies
- Jubilant Biosys
- Jubilant Life Sciences
- Juniper Pharma Services
- Juno Therapeutics
- KYORIN Pharmaceutical
- LabCorp
- Lead Discovery Center
- Leiden University
- Longthera Pharmaceuticals
- Lonza
- Marshall University
- Mascot Industries
- Max Planck Innovation
- Max Planck Institute of Biochemistry
- Medicilon
- Medivir
- Memorial Sloan Kettering Cancer Center
- Mercachem
- Merck Serono
- Merck Sharpe & Dohme
- Mir Lifescience
- Mirimus
- Moderna Therapeutics
- n3D Biosciences
- Nanjing Biotech Innovation Corporation
- Nanjing Legend Biotechnology
- Nanosyn
- National Cancer Institute
- National Resource Center for Mutant Mice
- National University of Singapore
- NEOMED Institute
- New England Discovery Partners
- Nile Scan & Labs
- Nimbus Therapeutics
- NovAliX
- NuChem Therapeutics
- OcellO
- Oncompass Medicine
- Oncotest
- Oncotyrol
- Ontario Institute for Cancer Research
- Onyx Scientific
- Organix
- OriBase Pharma
- Orion Corporation
- OTAVAchemicals
- OXELTIS
- Oxford Bioscience Partners
- Oxford University
- Paraza Pharma
- Paterson Institute for Cancer Research
- Pepscan
- PerkinElmer
- Pfizer
- Pharmaceutical Product Development
- PharmAgra Labs
- Pharmaron
- Pharminox
- PHENOMIN-ICS
- Piramal Pharma Solutions
- Prestwick Chemical
- Proteros
- Provid Pharmaceuticals
- Queen's University Belfast
- Quotient Bioresearch
- Qurient
- Radboud University
- Ratnamani Healthcare
- Reach Separations
- Red Glead Discovery
- Redx Pharma
- Regen BioPharma
- Roche
- RTI International
- Sage Laboratories
- Sai Life Sciences
- SAMDI Tech
- Sanofi
- Sapient Discovery
- SARomics Biostructures
- SBH Sciences
- Schrödinger
- Selcia
- Selvita
- Semmelweis University
- Shanghai ChemPartner
- ShangPharma
- Shionogi
- SRI Biosciences
- Stanford University
- Sundia MediTech
- Sygnature Discovery
- Syncom Healthcare
- Syngene
- Synvolux Therapeutics
- Taros Chemicals
- TATA Group
- Tata Trusts
- TC Scientific
- TCG Lifesciences
- The Agency for Science, Technology and Research
- The Eskitis Institute for Drug Discovery
- The European Molecular Biology Laboratory
- The Milner Therapeutics Institute
- The Ohio State University Comprehensive Cancer Center
- The Rockefeller University
- The Scripps Research Institute
- The University Medical Center Groningen
- The University of Texas MD Anderson Cancer Center
- The Wellcome Trust Sanger Institute
- Thermo Fisher Scientific
- Translational Drug Development
- Translational Genomics Research Institute
- Tri-Institutional Therapeutics Discovery Institute
- Tybema BioSolutions
- UbiQ
- Ubiquigent
- UCB Biopharma
- United BioPharma
- Univalor
- University College London
- University of California, Berkeley
- University of Cambridge
- University of Montreal
- University of Strasbourg
- University of Tsukuba
- University of Wisconsin-Madison: School of Pharmacy
- Vanta Bioscience
- Vichem Chemie
- Villapharma Research
- ViroStatics
- Viva Biotech
- Wageningen University
- Weill Cornell Medicine
- WIL Research
- WuXi AppTec
- York University
- Zenith Technologies
- ZoBio
- École Polytechnique Fédérale de Lausanne
For more information about this report visit https://www.researchandmarkets.com/research/jgd49j/oncology_drug
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/oncology-drug-discovery-services-market-2030-300494536.html
SOURCE Research and Markets
